LIKMEZ Drug Patent Profile

✉ Email this page to a colleague

When do Likmez patents expire, and what generic alternatives are available?

Likmez is a drug marketed by Saptalis Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has five patent family members in five countries.

The generic ingredient in LIKMEZ is metronidazole. There are eighteen drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the metronidazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Likmez

A generic version of LIKMEZ was approved as metronidazole by TEVA PHARMS USA on November 6^th, 1984.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for LIKMEZ?
What are the global sales for LIKMEZ?
What is Average Wholesale Price for LIKMEZ?

Summary for LIKMEZ

International Patents:	5
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Drug Prices:	Drug price information for LIKMEZ
What excipients (inactive ingredients) are in LIKMEZ?	LIKMEZ excipients list
DailyMed Link:	LIKMEZ at DailyMed

Drug patent expirations by year for LIKMEZ

Pharmacology for LIKMEZ

Drug Class	Nitroimidazole Antimicrobial

US Patents and Regulatory Information for LIKMEZ

LIKMEZ is protected by one US patents.

Patents protecting LIKMEZ

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Saptalis Pharms	LIKMEZ	metronidazole	SUSPENSION;ORAL	216755-001	Sep 22, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for LIKMEZ

See the table below for patents covering LIKMEZ around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2019140516		⤷ Sign Up
Canada	3087789	FORMULATIONS ORALES DE METRONIDAZOLE ET METHODES DE TRAITEMENT D'UNE INFECTION FAISANT APPEL A CELLES-CI (ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME)	⤷ Sign Up
European Patent Office	3768321	FORMULATIONS ORALES DE MÉTRONIDAZOLE ET MÉTHODES DE TRAITEMENT D'UNE INFECTION FAISANT APPEL À CELLES-CI (ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME)	⤷ Sign Up
Brazil	112020014376	composição farmacêutica oral, e, método para tratar uma infecção em um paciente.	⤷ Sign Up
Mexico	2020007494	FORMULACIONES ORALES DE METRONIDAZOL Y METODOS DE TRATAMIENTO DE UNA INFECCION CON LAS MISMAS. (ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME.)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for LIKMEZ

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0328535	96C0021	Belgium	⤷ Sign Up	PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

AI Research Assistant

Questions you can ask:

Summary for LIKMEZ

Pharmacology for LIKMEZ

Patents protecting LIKMEZ

Make Better Decisions: Try a trial or see plans & pricing